Article ID Journal Published Year Pages File Type
8453960 Lung Cancer 2018 24 Pages PDF
Abstract
We investigated the osimertinib resistance mechanism in a small cohort of lung adenocarcinoma patients, and demonstrated MET amplification was correlated with inferior PFS/OS after osimertinib treatment. Moreover, we reported the first clinical evidence of efficacy generated by combination of first-generation EGFR-TKI icotinib and crizotinib after the resistance to osimertinib.
Keywords
Related Topics
Life Sciences Biochemistry, Genetics and Molecular Biology Cancer Research
Preview
Clinical analysis by next-generation sequencing for NSCLC patients with MET amplification resistant to osimertinib
Authors
, , , , , ,